Partners

Immutep Logo_high resulution

Immutep

Immutep is a globally active biotechnology company that is a leader in the development of LAG-3 related immunotherapeutic products for the treatment of cancer and autoimmune disease. Immutep is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders.  The company is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States. 

Immutep’s current lead product candidate is eftilagimod alpha.

 

Website: www.immutep.com